Evidence map›Paper›PMID 23831852›Full record

Trial reportStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2013

Radiotherapy in pediatric pilocytic astrocytomas. A subgroup analysis within the prospective multicenter study HIT-LGG 1996 by the German Society of Pediatric Oncology and Hematology (GPOH).

K Müller, A Gnekow, F Falkenstein, J Scheiderbauer, I Zwiener, T Pietsch, M Warmuth-Metz, J Voges, G Nikkhah, M Flentje and 4 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Article
  4. Radiotherapy for pediatric low-grade glioma.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024
    Review
  5. Long-term treatment outcomes of pediatric low-grade gliomas treated at a university-based hospital.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2023
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Conventional chemotherapy and perspectives for molecular-based oncological treatment in pediatric hemispheric low-grade gliomas.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2016
    Review
  15. Management of pediatric intracranial low-grade gliomas: long-term follow-up after radiation therapy.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2016
    Article
  16. Article
  17. Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015
    Review
  18. De novo formation of brain tumors in pediatric population following therapeutic cranial irradiation.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2015
    Article
  19. Molecular insights into pediatric brain tumors have the potential to transform therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014
    Review
  20. Dynamics of fertility impairment in childhood brain tumour survivors.Journal of cancer research and clinical oncology · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

K MüllerDepartment of Radiotherapy and Radiation-Oncology, University of Leipzig, Stephanstr. 9A, 04103, Leipzig, Germany. Klaus.Mueller@medizin.uni-leipzig.de
A Gnekow
F Falkenstein
J Scheiderbauer
I Zwiener
T Pietsch
M Warmuth-Metz
J Voges
G Nikkhah
M Flentje
S E Combs
D Vordermark
M Kocher
R-D Kortmann
University Hospital Augsburg · DEUniversity of Würzburg · DEHeidelberg University · DEUniversitätsklinikum Erlangen · DEUniversity Hospital Leipzig · DEUniversity Hospital Magdeburg · DEUniversity Medical Center of the Johannes Gutenberg University Mainz · DEUniversity of Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe evaluated clinical outcomes in the subset of patients who underwent radiotherapy (RT) due to progressive pilocytic astrocytoma within the Multicenter Treatment Study for Children and Adolescents with a Low Grade Glioma HIT-LGG 1996. PATIENTS AND

methodsEligibility criteria were fulfilled by 117 patients. Most tumors (65 %) were located in the supratentorial midline, followed by the posterior fossa (26.5 %) and the cerebral hemispheres (8.5 %). Median age at the start of RT was 9.2 years (range 0.7-17.4 years). In 75 cases, external fractionated radiotherapy (EFRT) was administered either as first-line nonsurgical treatment (n = 58) or after progression following primary chemotherapy (n = 17). The median normalized total dose was 54 Gy. Stereotactic brachytherapy (SBT) was used in 42 selected cases.

resultsDuring a median follow-up period of 8.4 years, 4 patients (3.4 %) died and 33 (27.4 %) experienced disease progression. The 10-year overall (OS) and progression-free survival (PFS) rates were 97 and 70 %, respectively. No impact of the RT technique applied (EFRT versus SBT) on progression was observed. The 5-year PFS was 76 ± 5 % after EFRT and 65 ± 8 % after SBT. Disease progression after EFRT was not influenced by gender, neurofibromatosis type 1 (NF1) status, tumor location (hemispheres versus supratentorial midline versus posterior fossa), age or prior chemotherapy. Normalized total EFRT doses of more than 50.4 Gy did not improve PFS rates.

conclusionEFRT plays an integral role in the treatment of pediatric pilocytic astrocytoma and is characterized by excellent tumor control. A reduction of the normalized total dose from 54 to 50.4 Gy appears to be feasible without jeopardizing tumor control. SBT is an effective treatment alternative.

Indexed as

AdolescentAstrocytomaBrachytherapyBrain NeoplasmsChildDisease-Free SurvivalFemaleGermanyHumansMalePrevalenceProspective StudiesTreatment OutcomeYoung Adult

Identifiers

PMID23831852
OpenAlexW199018966

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.